- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 3.5 Certificate of Incorporation of Morphogenesis, Inc., As Currently In Effect
- 3.6 Bylaws of Morphogenesis, Inc., As Currently In Effect
- 4.9 Form of Morphogenesis, Inc. Common Stock Purchase Warrant Issued In Series a Preferred Stock Offering
- 4.10 Form of Morphogenesis, Inc. Common Stock Purchase Warrant, Dated June 1, 2019, Issued for Advisory Services
- 4.11 Form of Morphogenesis, Inc. Common Stock Purchase Warrant Issued In Series A-1 Preferred Offering
- 4.12 Form of Morphogenesis, Inc. Common Stock Purchase Warrant Issued In Note Conversion Transaction
- 4.13 Form of Morphogenesis, Inc. Common Stock Purchase Warrant Issued In Series B Preferred Stock Offering
- 10.21 Amended and Restated Equity Plan of Morphogenesis, Inc
- 10.22 Form of Option Agreement Under the Amended and Restated Equity Plan of Morphogenesis, Inc
- 10.23 First Amended and Restated Employment Agreement, Dated May 22, 2023, Between Morphogenesis, Inc. and Dan Dearborn
- 10.24 First Amended and Restated Employment Agreement, Dated May 22, 2023, Between Morphogenesis, Inc. and James Bianco, M.D
- 10.25 Consulting Agreement, Dated July 1, 2021, Between Morphogenesis, Inc. and Wyaldkatz, LLC
- 10.26 Amendment, Dated February 14, 2022, to Consulting Agreement, Dated July 1, 2021, Between Morphogenesis, Inc. and Wyaldkatz, LLC
- 23.1 Consent of Marcum LLP, Independent Registered Public Accounting Firm of Cohbar, Inc
- 23.2 Consent of Cherry Bekaert LLP, Independent Registered Public Accounting Firm of Morphogenesis, Inc
- 99.3 Consent of James Manuso to Serve As a Director of Cohbar, Inc., to Be Renamed Tuhura Biosciences, Inc.
- 99.4 Consent of James Bianco, M.D. to Serve As a Director of Cohbar, Inc., to Be Renamed Tuhura Biosciences, Inc.
- 99.5 Consent of Alan List, M.D. to Serve As a Director of Cohbar, Inc., to Be Renamed Tuhura Biosciences, Inc.
- 99.6 Consent of George NG to Serve As a Director of Cohbar, Inc., to Be Renamed Tuhura Biosciences, Inc.
- 99.7 Consent of Ladenburg Thalmann & Co. Inc.
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
- 13 Sep 23 EFFECT Notice of effectiveness
- 12 Sep 23 424B3 Prospectus supplement
- 12 Sep 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 29 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 10 Aug 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
30 Jun 23 S-4 Registration of securities issued in business combination transactions
- 12 Sep 23 Registration of securities issued in business combination transactions (amended)
- 29 Aug 23 Registration of securities issued in business combination transactions (amended)
- 10 Aug 23 Registration of securities issued in business combination transactions (amended)
- 30 Jun 23 Registration of securities issued in business combination transactions
Exhibit 10.26
AMENDMENT TO WYLDKATZ, LLC CONSULTING
AGREEMENT WITH MORPHOGENESIS, INC.
The undersigned, being the Principals of Wyldkatz, LLC, a Florida limited liability company, and Morphogenesis, Inc, (the “Company”) a Florida corporation hereby amend their Consulting Agreement dated July 1, 2021. The amendment shall solely consist of the following replacement of Section 3A:
Term. This Agreement shall remain in effect through (and including) December 31, 2023 (“Scheduled Termination Date”), unless earlier terminated in accordance with this Section 3. For clarity, the failure by the Company to request any Services from Consultant shall not terminate this agreement.
The remaining Wyldkatz consulting agreement, other than Section 3A above, shall remain valid and enforceable.
Dated: February 14, 2022.
Wyldkatz, LLC:
/s/ Michael Lawman | |
Michael Lawman |
/s/ Patricia Lawman | |
Patricia Lawman |
Morphogenesis, Inc
/s/ Dam Dearborn | |
Dan Dearborn, CFO |